Merck Pays Big To Expand Into Acute Care With Cubist Acquisition (Updated)
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck agreed to pay $9.5 billion to acquire Cubist, gaining a portfolio of antibiotics for hard-to-treat infections as part of a broader strategy to expand in the acute care setting.